author-photo

Reyes Bernabe Caro

25

Papers

950

Citations

Citation Trend

Filter By

Papers (22) Sort By

Journal Conference Others

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
FP10.04 RESILIENT Part 1: Safety and Efficacy of Second-Line Liposomal Irinotecan in Patients with Small Cell Lung Cancer

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial.

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis.

2021 Journal of Clinical Medicine
Show All
- Source
- Cite
- Save
Citations (1)
Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
PD-(L)1 inhibitors as monotherapy for the first-line treatment of non-small cell lung cancer patients with high PD-L1 expression: A network meta-analysis.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
P48.14 RESILIENT Part 2: A phase 3 Study of Liposomal Irinotecan in Patients with Small-Cell Lung Cancer in the Second-Line Setting

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT221: Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment for patients with advanced non-small cell lung cancer (NSCLC) with brain metastases: Results from CheckMate 227

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (6)
Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy

2020 Cancers
Show All
- Source
- Cite
- Save
Citations (10)